Cell Cycle/Checkpoint
Cell Cycle
Cells undergo a complex cycle of growth and division that is referred to as the cell cycle. The cell cycle consists of four phases, G1 (GAP 1), S (synthesis), G2 (GAP 2) and M (mitosis). DNA replication occurs during S phase. When cells stop dividing temporarily or indefinitely, they enter a quiescent state called G0.
Research Areas
- ATM/ATR(26)
- Aurora Kinase(31)
- Cdc42(4)
- Cdc7(3)
- Chk(13)
- c-Myc(41)
- CRM1(9)
- Cyclin-Dependent Kinases(70)
- E1 enzyme(1)
- G-quadruplex(13)
- Haspin(5)
- HMTase(1)
- Kinesin(29)
- Ksp(4)
- Microtubule/Tubulin(276)
- Mps1(14)
- Mitotic(7)
- RAD51(13)
- ROCK(72)
- Rho(13)
- PERK(18)
- PLK(46)
- PTEN(7)
- Wee1(11)
- PAK(28)
- Arp2/3 Complex(10)
- Dynamin(16)
- ECM & Adhesion Molecules(53)
- Cholesterol Metabolism(10)
- Endomembrane System & Vesicular Trafficking(34)
- G1(50)
- G2/M(35)
- G2/S(16)
- Genotoxic Stress(22)
- Inositol Phosphates(65)
- Proteolysis(179)
- Cytoskeleton & Motor Proteins(71)
- Cellular Chaperones(14)
- Cyclin G-associated Kinase (GAK)(2)
- MARK(4)
- NEKs(6)
- ATF6(2)
- ClpP(5)
- Disulfidptosis(1)
- HMG Family(1)
- PDI(1)
- SWI/SNF Complex(4)
- VISTA(2)
- HOXA(1)
Products Related to Cell Cycle/Checkpoint(1463)
- GC78758Mal-Val-Lys-PAB-MMAE TFAPurity: >98.00%
Mal-Val-Lys-PAB-MMAE TFA is a drug-linker conjugate for ADC.
- GC78762Trastuzumab-DM4Purity: >98%
Trastuzumab -DM4 is an antibody-drug conjugate (ADC) formed by conjugating Trastuzumab with DM4 (sulfo-SPDB-DM4) via a cleavable linker.
- GC78763ADC Control Human IgG1-sulfo-SPDB-DM4Purity: >98.00%
ADC Control Human IgG1-sulfo-SPDB-DM4 is an antibody-drug conjugate (ADC) and can inhibit tubulin polymerization.
- GC78764Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAECAS: 3103526-19-5Purity: >97.50%
Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.
- GC78766N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan)Purity: >98.00%
N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE and a DNA topoisomerase I inhibitor Exatecan, and an ADC linker composition.
- GC78767N-(DBCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)Purity: >98.00%
N-(DBCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE and a DNA topoisomerase I inhibitor Exatecan, and an ADC linker composition.
- GC78956MYCMI-7 hydrobromideCAS: 102537-38-2Purity: >95.00%
MYCMI-7 hydrobromide is a potent and selective MYC/MYCN inhibitor, with a K d of 4 μM for MYC and an IC 50 of 10 μM for topoisomerase IIα ( Topoisomerase II α ).
- GC78959c-Myc NLS TFAPurity: >98.00%
c-Myc NLS TFA is a non-canonical nuclear localization signal (NLS) derived from the oncoprotein c-Myc, with the sequence PAAKRVKLD and containing 3 basic amino acids.
- GC79004PMV6-PEG4-BI2536Purity: >98.00%
PMV6-PEG4-BI2536 is an RIPTAC-like bifunctional molecule that promotes the formation of the p53 Y 220C -PLK1 ternary complex ( EC 50 = 1.4 μM).
- GC79009Tubulin polymerization-IN-84CAS: 2982893-14-9Purity: >99.50%
Tubulin polymerization-IN-84 inhibits tubulin polymerization by targeting the colchicine-binding pocket, with an IC 50 = 10.9 μM.
- GC790117-BenzoyloxindoleCAS: 51135-38-7Purity: >98%
7-Benzoyloxindole (Compound 4a) is a tubulin destabilizer.
- GC79014Tubulin inhibitor 49 hydrobromidePurity: >99.00%
Tubulin inhibitor 49 (Compound 18) hydrobromide is an inhibitor for tubulin polymerization with an IC 50 of 48 μM.
- GC79015Iso cephalomannineCAS: 173101-54-7Purity: >98%
Iso cephalomannine is a tubulin -targeting cytotoxic agent.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC78758 | Mal-Val-Lys-PAB-MMAE TFA | - | >98.00% | |
Mal-Val-Lys-PAB-MMAE TFA is a drug-linker conjugate for ADC. | ||||
| GC78762 | Trastuzumab-DM4 | - | >98% | |
Trastuzumab -DM4 is an antibody-drug conjugate (ADC) formed by conjugating Trastuzumab with DM4 (sulfo-SPDB-DM4) via a cleavable linker. | ||||
| GC78763 | ADC Control Human IgG1-sulfo-SPDB-DM4 | - | >98.00% | |
ADC Control Human IgG1-sulfo-SPDB-DM4 is an antibody-drug conjugate (ADC) and can inhibit tubulin polymerization. | ||||
| GC78764 | Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE | 3103526-19-5 | >97.50% | |
Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. | ||||
| GC78765 | LP-6 TFA | 1629741-09-8 | >98.00% | |
LP-6 TFA is a Drug-Linker Conjugate for ADC, and can be used for synthesis of ADCs. | ||||
| GC78766 | N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan) | - | >98.00% | |
N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE and a DNA topoisomerase I inhibitor Exatecan, and an ADC linker composition. | ||||
| GC78767 | N-(DBCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) | - | >98.00% | |
N-(DBCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE and a DNA topoisomerase I inhibitor Exatecan, and an ADC linker composition. | ||||
| GC78791 | AMG-172 | - | >98% | |
AMG-172 is an antibody-drug conjugate ( ADC ) composed of a fully human IgG1 monoclonal anti- CD27L antibody conjugated to DM1 via the non-cleavable linker MCC. | ||||
| GC78798 | NN3201 | - | >99.00% | |
NN3201 is a c-Kit -targeting antibody-drug conjugate ( ADC ) with high affinity ( K D = 0.19 pM). | ||||
| GC78956 | MYCMI-7 hydrobromide | 102537-38-2 | >95.00% | |
MYCMI-7 hydrobromide is a potent and selective MYC/MYCN inhibitor, with a K d of 4 μM for MYC and an IC 50 of 10 μM for topoisomerase IIα ( Topoisomerase II α ). | ||||
| GC78959 | c-Myc NLS TFA | - | >98.00% | |
c-Myc NLS TFA is a non-canonical nuclear localization signal (NLS) derived from the oncoprotein c-Myc, with the sequence PAAKRVKLD and containing 3 basic amino acids. | ||||
| GC78960 | DL78 | 132993-79-4 | >99.00% | |
DL78 is an effective anti-mitotic agent. | ||||
| GC78995 | ZY39 | 2999673-51-5 | >99.50% | |
ZY39 is a Sa ClpP agonist. | ||||
| GC79000 | Q901 TFA | - | >98.50% | |
Q901 (CDK7-IN-21) TFA is a selective and potent CDK7 inhibitor with an IC 50 of 10 nM. | ||||
| GC79004 | PMV6-PEG4-BI2536 | - | >98.00% | |
PMV6-PEG4-BI2536 is an RIPTAC-like bifunctional molecule that promotes the formation of the p53 Y 220C -PLK1 ternary complex ( EC 50 = 1.4 μM). | ||||
| GC79008 | WY165 | - | >99.00% | |
WY165 is a bifunctional molecule comprising TR79, an activator of the mitochondrial protease complex caseinolytic protease P ( ClpP ), linked to desthiobiotin. | ||||
| GC79009 | Tubulin polymerization-IN-84 | 2982893-14-9 | >99.50% | |
Tubulin polymerization-IN-84 inhibits tubulin polymerization by targeting the colchicine-binding pocket, with an IC 50 = 10.9 μM. | ||||
| GC79010 | DHTP | 1620225-37-7 | >99.00% | |
DHTP is a kinesin-13 family of microtubule depolymerases selective allosteric inhibitor that inhibits kinesin-13 ATPase activity and microtubule depolymerization activity. | ||||
| GC79011 | 7-Benzoyloxindole | 51135-38-7 | >98% | |
7-Benzoyloxindole (Compound 4a) is a tubulin destabilizer. | ||||
| GC79012 | Microtubule-IN-13 | - | >99.50% | |
Microtubule-IN-13 (Compound FB2) is a microtubule inhibitor. | ||||
| GC79013 | ON 01500 | 592542-50-2 | >99.00% | |
ON 01500 is a tubulin inhibitor with a K d of 21 nM. | ||||
| GC79014 | Tubulin inhibitor 49 hydrobromide | - | >99.00% | |
Tubulin inhibitor 49 (Compound 18) hydrobromide is an inhibitor for tubulin polymerization with an IC 50 of 48 μM. | ||||
| GC79015 | Iso cephalomannine | 173101-54-7 | >98% | |
Iso cephalomannine is a tubulin -targeting cytotoxic agent. | ||||
| GC79016 | KMG-732 | - | >98% | |
KMG-732 is a dual-target inhibitor that targets GAK and β-tubulin, with K d values of 12.0 nM and 19.3 μM, respectively. | ||||
